$ARRY Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ARRAY BIOPHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ARRAY BIOPHARMA INC. Get notifications about new insider transactions in ARRAY BIOPHARMA INC for free.
Page: < prev 1 2 3 4 5 6 7 ... 7 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Sell | S | 15.35 | 8,689 | 133,376 | 210,086 | 218.8 K to 210.1 K (-3.97 %) |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Payment of Exercise | F | 16.32 | 6,936 | 113,196 | 218,775 | 225.7 K to 218.8 K (-3.07 %) |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Buy | M | 0.00 | 7,812 | 0 | 225,711 | 217.9 K to 225.7 K (+3.59 %) |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | M | 0.00 | 6,875 | 0 | 13,750 | |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Payment of Exercise | F | 16.32 | 6,118 | 99,846 | 55,278 | 61.4 K to 55.3 K (-9.96 %) |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Buy | M | 0.00 | 6,875 | 0 | 61,396 | 54.5 K to 61.4 K (+12.61 %) |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 18,906 | 0 | 37,813 | |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 16.32 | 16,605 | 270,994 | 211,575 | 228.2 K to 211.6 K (-7.28 %) |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 0.00 | 18,906 | 0 | 228,180 | 209.3 K to 228.2 K (+9.03 %) |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 0.00 | 9,844 | 0 | 19,688 | |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Payment of Exercise | F | 16.32 | 8,675 | 141,576 | 159,467 | 168.1 K to 159.5 K (-5.16 %) |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 0.00 | 9,844 | 0 | 168,142 | 158.3 K to 168.1 K (+6.22 %) |
| Mar 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 3.51 | 14,500 | 50,895 | 5,500 | ||
| Mar 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 3.37 | 7,000 | 23,590 | 0 | ||
| Mar 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Sell | S | 16.76 | 21,500 | 360,340 | 19,297 | 40.8 K to 19.3 K (-52.70 %) | |
| Mar 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 3.51 | 14,500 | 50,895 | 40,797 | 26.3 K to 40.8 K (+55.14 %) | |
| Mar 21 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 3.37 | 7,000 | 23,590 | 26,297 | 19.3 K to 26.3 K (+36.28 %) | |
| Mar 09 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | M | 3.65 | 182,191 | 664,997 | 379,259 | |
| Mar 09 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Sell | S | 17.72 | 111,518 | 1,976,099 | 217,899 | 329.4 K to 217.9 K (-33.85 %) |
| Mar 09 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Sell | S | 17.70 | 44,498 | 787,615 | 329,417 | 373.9 K to 329.4 K (-11.90 %) |
| Mar 09 2018 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Buy | M | 3.65 | 182,191 | 664,997 | 373,915 | 191.7 K to 373.9 K (+95.03 %) |
| Feb 23 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 2.46 | 13,500 | 33,210 | 0 | ||
| Feb 23 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 2.46 | 13,500 | 33,210 | 0 | ||
| Feb 23 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 3.37 | 8,000 | 26,960 | 7,000 | ||
| Feb 23 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 3.37 | 8,000 | 26,960 | 7,000 | ||
| Feb 23 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Sell | S | 17.16 | 21,500 | 368,940 | 19,297 | 40.8 K to 19.3 K (-52.70 %) | |
| Feb 23 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Sell | S | 17.16 | 21,500 | 368,940 | 19,297 | 40.8 K to 19.3 K (-52.70 %) | |
| Feb 23 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 3.37 | 8,000 | 26,960 | 40,797 | 32.8 K to 40.8 K (+24.39 %) | |
| Feb 23 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 3.37 | 8,000 | 26,960 | 40,797 | 32.8 K to 40.8 K (+24.39 %) | |
| Feb 23 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 2.46 | 13,500 | 33,210 | 32,797 | 19.3 K to 32.8 K (+69.96 %) | |
| Feb 23 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 2.46 | 13,500 | 33,210 | 32,797 | 19.3 K to 32.8 K (+69.96 %) | |
| Feb 12 2018 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | M | 3.87 | 25,000 | 96,750 | 0 | ||
| Feb 12 2018 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | M | 5.60 | 25,000 | 140,000 | 0 | ||
| Feb 12 2018 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Sell | S | 17.01 | 50,000 | 850,500 | 17,720 | 67.7 K to 17.7 K (-73.83 %) | |
| Feb 12 2018 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Buy | M | 3.87 | 25,000 | 96,750 | 67,720 | 42.7 K to 67.7 K (+58.52 %) | |
| Feb 12 2018 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Buy | M | 5.60 | 25,000 | 140,000 | 42,720 | 17.7 K to 42.7 K (+141.08 %) | |
| Feb 12 2018 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Option Exercise | M | 5.13 | 25,000 | 128,250 | 0 | ||
| Feb 12 2018 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Option Exercise | M | 5.95 | 25,000 | 148,750 | 0 | ||
| Feb 12 2018 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Sell | S | 16.90 | 50,000 | 845,000 | 10,000 | 60 K to 10 K (-83.33 %) | |
| Feb 12 2018 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Buy | M | 5.13 | 25,000 | 128,250 | 60,000 | 35 K to 60 K (+71.43 %) | |
| Feb 12 2018 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Buy | M | 5.95 | 25,000 | 148,750 | 35,000 | 10 K to 35 K (+250.00 %) | |
| Jan 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 1.74 | 15,000 | 26,100 | 0 | ||
| Jan 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 2.46 | 6,500 | 15,990 | 13,500 | ||
| Jan 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Sell | S | 12.94 | 21,500 | 278,210 | 19,297 | 40.8 K to 19.3 K (-52.70 %) | |
| Jan 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 2.46 | 6,500 | 15,990 | 40,797 | 34.3 K to 40.8 K (+18.95 %) | |
| Jan 17 2018 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 1.74 | 15,000 | 26,100 | 34,297 | 19.3 K to 34.3 K (+77.73 %) | |
| Jan 16 2018 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Option Exercise | M | 3.77 | 14,025 | 52,874 | 540,975 | |
| Jan 16 2018 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Sell | S | 13.73 | 7,500 | 102,975 | 28,868 | 36.4 K to 28.9 K (-20.62 %) |
| Jan 16 2018 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Buy | M | 3.77 | 14,025 | 52,874 | 36,368 | 22.3 K to 36.4 K (+62.77 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Option Exercise | A | 10.92 | 168,000 | 1,834,560 | 168,000 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Option Exercise | A | 0.00 | 28,000 | 0 | 28,000 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Option Exercise | A | 10.92 | 168,000 | 1,834,560 | 168,000 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Option Exercise | A | 0.00 | 28,000 | 0 | 28,000 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Option Exercise | M | 0.00 | 4,387 | 0 | 13,163 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Payment of Exercise | F | 10.92 | 2,044 | 22,320 | 22,343 | 24.4 K to 22.3 K (-8.38 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Buy | M | 0.00 | 4,387 | 0 | 24,387 | 20 K to 24.4 K (+21.94 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 4.63 | 87,500 | 405,125 | 87,500 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 4.91 | 89,634 | 440,103 | 0 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 4.91 | 20,366 | 99,997 | 0 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 5.14 | 200,000 | 1,028,000 | 0 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | A | 10.92 | 335,250 | 3,660,930 | 335,250 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | A | 0.00 | 55,875 | 0 | 55,875 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 0.00 | 13,082 | 0 | 39,249 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Sell | S | 10.72 | 282,874 | 3,032,409 | 158,298 | 441.2 K to 158.3 K (-64.12 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 4.63 | 87,500 | 405,125 | 441,172 | 353.7 K to 441.2 K (+24.74 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 4.91 | 89,634 | 440,103 | 353,672 | 264 K to 353.7 K (+33.95 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 4.91 | 20,366 | 99,997 | 264,038 | 243.7 K to 264 K (+8.36 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 5.14 | 200,000 | 1,028,000 | 243,672 | 43.7 K to 243.7 K (+457.96 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Payment of Exercise | F | 10.92 | 6,094 | 66,546 | 43,672 | 49.8 K to 43.7 K (-12.25 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 0.00 | 13,082 | 0 | 49,766 | 36.7 K to 49.8 K (+35.66 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | A | 10.92 | 168,000 | 1,834,560 | 168,000 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | A | 0.00 | 28,000 | 0 | 28,000 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | M | 0.00 | 5,468 | 0 | 16,407 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Payment of Exercise | F | 10.92 | 2,548 | 27,824 | 54,521 | 57.1 K to 54.5 K (-4.46 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Buy | M | 0.00 | 5,468 | 0 | 57,069 | 51.6 K to 57.1 K (+10.60 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 5.94 | 333,165 | 1,979,000 | 0 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 4.63 | 79,688 | 368,955 | 345,312 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 3.61 | 133,380 | 481,502 | 755,820 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 3.61 | 110,800 | 399,988 | 0 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 5.94 | 16,835 | 100,000 | 0 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 7.30 | 226,874 | 1,656,180 | 226,876 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 10.92 | 600,000 | 6,552,000 | 600,000 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 0.00 | 100,000 | 0 | 100,000 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 23,437 | 0 | 70,313 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 10.93 | 546,233 | 5,970,327 | 209,274 | 755.5 K to 209.3 K (-72.30 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 5.94 | 333,165 | 1,979,000 | 755,507 | 422.3 K to 755.5 K (+78.89 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 4.63 | 79,688 | 368,955 | 422,342 | 342.7 K to 422.3 K (+23.26 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 3.61 | 133,380 | 481,502 | 342,654 | 209.3 K to 342.7 K (+63.73 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 10.73 | 273,438 | 2,933,990 | 209,274 | 482.7 K to 209.3 K (-56.65 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 3.61 | 110,800 | 399,988 | 482,712 | 371.9 K to 482.7 K (+29.79 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 5.94 | 16,835 | 100,000 | 371,912 | 355.1 K to 371.9 K (+4.74 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 7.30 | 226,874 | 1,656,180 | 355,077 | 128.2 K to 355.1 K (+176.96 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 10.92 | 10,917 | 119,214 | 128,203 | 139.1 K to 128.2 K (-7.85 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 0.00 | 23,437 | 0 | 139,120 | 115.7 K to 139.1 K (+20.26 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | A | 10.92 | 289,500 | 3,161,340 | 289,500 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | A | 0.00 | 48,250 | 0 | 48,250 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | M | 0.00 | 11,284 | 0 | 33,854 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Payment of Exercise | F | 10.92 | 5,310 | 57,985 | 191,724 | 197 K to 191.7 K (-2.69 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Buy | M | 8.79 | 11,284 | 99,186 | 197,034 | 185.8 K to 197 K (+6.07 %) |
| Nov 13 2017 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Sell | D | 10.90 | 1,035 | 11,282 | 19,297 | 20.3 K to 19.3 K (-5.09 %) | |
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | A | 10.47 | 25,000 | 261,750 | 25,000 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 10.47 | 5,000 | 52,350 | 20,332 | 15.3 K to 20.3 K (+32.61 %) | |
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Option Exercise | A | 10.47 | 25,000 | 261,750 | 25,000 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | Orwin John A | Buy | M | 10.47 | 5,000 | 52,350 | 10,000 | 5 K to 10 K (+100.00 %) | |
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | A | 10.47 | 25,000 | 261,750 | 25,000 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Buy | M | 10.47 | 5,000 | 52,350 | 17,720 | 12.7 K to 17.7 K (+39.31 %) | |
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Option Exercise | A | 10.47 | 25,000 | 261,750 | 25,000 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | BAUM CHARLES M | Buy | M | 10.47 | 5,000 | 52,350 | 10,000 | 5 K to 10 K (+100.00 %) | |
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | Sharp Shalini | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | Sharp Shalini | Option Exercise | A | 10.47 | 25,000 | 261,750 | 25,000 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Option Exercise | A | 10.47 | 25,000 | 261,750 | 25,000 | ||
| Oct 27 2017 | ARRY | ARRAY BIOPHARMA IN ... | Fyfe Gwen A. | Buy | M | 10.47 | 5,000 | 52,350 | 10,000 | 5 K to 10 K (+100.00 %) | |
| Sep 29 2017 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Option Exercise | M | 10.58 | 45,000 | 476,100 | 0 | ||
| Sep 29 2017 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Sell | S | 12.36 | 39,928 | 493,510 | 15,332 | 55.3 K to 15.3 K (-72.25 %) | |
| Sep 29 2017 | ARRY | ARRAY BIOPHARMA IN ... | VAN LUNSEN GIL J | Buy | M | 10.58 | 45,000 | 476,100 | 55,260 | 10.3 K to 55.3 K (+438.60 %) | |
| Sep 29 2017 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | M | 10.58 | 45,000 | 476,100 | 0 | ||
| Sep 29 2017 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Sell | S | 12.31 | 38,865 | 478,428 | 12,720 | 51.6 K to 12.7 K (-75.34 %) | |
| Sep 29 2017 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Buy | M | 10.58 | 45,000 | 476,100 | 51,585 | 6.6 K to 51.6 K (+683.37 %) | |
| Aug 15 2017 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Option Exercise | M | 3.77 | 20,000 | 75,400 | 555,000 | |
| Aug 15 2017 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Buy | M | 3.77 | 20,000 | 75,400 | 20,000 | 0 to 20 K |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 18,906 | 0 | 56,719 | |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 8.94 | 12,042 | 107,655 | 114,327 | 126.4 K to 114.3 K (-9.53 %) |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 0.00 | 18,906 | 0 | 126,369 | 107.5 K to 126.4 K (+17.59 %) |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Option Exercise | M | 0.00 | 7,812 | 0 | 23,438 | |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Payment of Exercise | F | 8.94 | 5,022 | 44,897 | 172,406 | 177.4 K to 172.4 K (-2.83 %) |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Sandor Victor | Chief Medical Offic ... | Buy | M | 0.00 | 7,812 | 0 | 177,428 | 169.6 K to 177.4 K (+4.61 %) |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | M | 0.00 | 6,875 | 0 | 20,625 | |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Payment of Exercise | F | 8.94 | 4,535 | 40,543 | 37,526 | 42.1 K to 37.5 K (-10.78 %) |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Buy | M | 0.00 | 6,875 | 0 | 42,061 | 35.2 K to 42.1 K (+19.54 %) |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 0.00 | 9,843 | 0 | 29,532 | |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Payment of Exercise | F | 8.94 | 6,293 | 56,259 | 39,558 | 45.9 K to 39.6 K (-13.72 %) |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 0.00 | 9,843 | 0 | 45,851 | 36 K to 45.9 K (+27.34 %) |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Option Exercise | M | 0.00 | 6,718 | 0 | 20,157 | |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Payment of Exercise | F | 8.94 | 4,408 | 39,408 | 42,064 | 46.5 K to 42.1 K (-9.49 %) |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | MOORE JOHN R | VP, General Counsel | Buy | M | 0.00 | 6,718 | 0 | 46,472 | 39.8 K to 46.5 K (+16.90 %) |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | M | 4.36 | 20,000 | 87,200 | 0 | ||
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | M | 3.69 | 25,000 | 92,250 | 0 | ||
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Sell | S | 8.92 | 45,000 | 401,400 | 6,585 | 51.6 K to 6.6 K (-87.23 %) | |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Buy | M | 4.36 | 20,000 | 87,200 | 51,585 | 31.6 K to 51.6 K (+63.32 %) | |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Buy | M | 3.69 | 25,000 | 92,250 | 31,585 | 6.6 K to 31.6 K (+379.65 %) |